Sofosbuvir Patent Challenge Could Highlight Weaknesses In IP Systems
NGOs from across Europe are challenging a patent protecting Gilead’s Sovaldi in an effort to expand patient access to hepatitis C treatments. They say the case will also expose failings in the intellectual property rights system that hinder access to innovation.
You may also be interested in...
NGOs are continuing their efforts to pave the way for lower-cost generic versions of Gilead’s breakthrough hepatitis C treatment Sovaldi and have appealed a decision by the European Patent Office to uphold a key patent relating to the drug.
A challenge brought to the European Patent Office that sought to open the door to generic competition to Gilead’s hepatitis C treatment has failed.
Advocacy groups want the WHO's proposed roadmap on improving access to medicines to include stronger language on transparency of R&D costs, prices and revenues. The pharmaceutical industry, however, believes any forward-looking solution should rest upon strong IP protection.